CLAIMS

1. Use of an injectable composition comprising a carbohydrate in the manufacture of a medicament for treating an injured tendon in an animal or human, wherein:

said composition comprises an effective amount of carbohydrate to increase tendon hydration and lubrication at the osteotendinous junction;

said medicament is to be administered via intra-osteotendinous injection at zone one, zone two, zone three, or zone four of the osteotendinous junction; and

wherein said carbohydrate comprises hyaluronic acid, or an ester, acylurea, acyl isourea, disulfide, or amide thereof.

2. The use of claim 1, wherein said carbohydrate has a molecular mass of 1,000,000 to 3,000,000 Daltons.

3. The use of any preceding claim, wherein said carbohydrate is at least 1% by mole percent cross-linked.

4. The use of any preceding claim, wherein said carbohydrate is present in said composition at a concentration of 5-30 mg/mL.

5. The use of any preceding claim, wherein said injectable composition further comprises at least one carbohydrate selected from the group consisting of collagen, gelatin, a polysaccharide, and combinations thereof.

6. The use of any preceding claim, wherein said injectable composition further comprises a polysaccharide.

7. The use of any preceding claim, wherein said hyaluronic acid, or an ester, acylurea, acyl isourea, disulfide, or amide thereof is derived from bacteria or animals.

8. The use of any preceding claim, wherein said hyaluronic acid is selected from the group consisting of hyaluronan, sodium hyaluronate, potassium hyaluronate, magnesium hyaluronate, calcium hyaluronate, ammonium hyaluronate, and combinations thereof.

9. The use of any preceding claim, wherein said hyaluronic acid comprises a hyaluronic ester.

10. The use of any preceding claim, wherein said hyaluronic acid comprises a hyaluronic amide.

11. The use of any preceding claim, wherein said medicament is to be administered at a site distal from the musculotendinous junction.

12. The use of any preceding claim, with the proviso that said medicament is not to be administered via peri-musculotendinous or intra-musculotendinous injection.

13. The use of any one of claims 1-2 or 4-12, wherein said carbohydrate is not cross-linked.

14, The use of any preceding claim, wherein said injectable composition further comprises a recombinant protein.

15. The use of any preceding claim, wherein said injectable composition further comprises a small molecule.

16. The use of any preceding claim, wherein said injectable composition further comprises one or more of a somatic cell, platelet rich plasma (PRP), platelet poor plasma (PPP), stem cell allografts, stem cell autografts, bone marrow aspirate (BMA), bone marrow aspirate concentrate (BMAC), autologous fibroblast, or autologous myoblasts.

17. The use of any preceding claim, where said carbohydrate contains at least one functional group selected from the group consisting of thiols, alcohols, amines, carboxyl groups, aldehydes, amides, esters, ketones, and combinations thereof.

18. The use of any preceding claim, wherein said injectable composition is in the form of a hydrogel.